Natera's Signatera to Guide CDK4/6 Therapy in Global Phase III Breast Cancer Trial
NTRA has more than doubled off its 52-week low of $157.425.
Summary
Natera and Alliance Foundation Trials launched AFT-70 NAVIGATE, a global Phase III trial testing whether Signatera MRD monitoring can safely spare some early breast cancer patients from CDK4/6 inhibitors. The trial will enroll over 2,000 patients at 200 sites, pairing Genentech's giredestrant with Signatera-guided escalation. This is a major validation of Signatera's utility in a large, practice-changing adjuvant setting. Success could expand Signatera's use in breast cancer and strengthen Natera's oncology franchise. The trial's primary endpoint is 4-year distant recurrence-free survival, with results likely years away.
At the time of this announcement, NTRA was trading at $409.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.1B. The 52-week trading range was $157.43 to $427.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.